Response to IpilimumabNivolumab Rechallenge and BRAF InhibitorMEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
المؤلفون المشاركون
Myrdal, Caitlyn N.
Sundararajan, Srinath
المصدر
Case Reports in Oncological Medicine
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-06-25
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Little is known about the optimal sequencing of targeted therapy and immunotherapy in the treatment of patients with BRAFV600-mutated metastatic melanoma.
BRAF/MEK inhibition often has the benefit of rapid disease regression; however, resistance is frequently seen with long-term use.
Treatment with immune checkpoint inhibitors offers the potential for long-term response but displays a lower rate of objective response.
The benefit of synergy between therapies is apparent; however, there is limited data regarding optimal sequencing in the treatment of advanced melanoma.
We present the case of a 62-year-old gentleman with advanced BRAFV600-mutated melanoma who followed an unconventional treatment path.
After progressing on single-agent vemurafenib, he had response to multiple modalities of immunotherapy before progression.
After, he had a substantial response to multiple BRAF/MEK inhibitor rechallenges before developing resistance.
The patient is now stable after a retrial of combination immunotherapy.
Our case illustrates that with the right sequencing of therapy, meaningful clinical responses can be elicited with rechallenging of targeted therapy and immunotherapy in metastatic melanoma.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Myrdal, Caitlyn N.& Sundararajan, Srinath. 2020. Response to IpilimumabNivolumab Rechallenge and BRAF InhibitorMEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy. Case Reports in Oncological Medicine،Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1149406
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Myrdal, Caitlyn N.& Sundararajan, Srinath. Response to IpilimumabNivolumab Rechallenge and BRAF InhibitorMEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy. Case Reports in Oncological Medicine No. 2020 (2020), pp.1-6.
https://search.emarefa.net/detail/BIM-1149406
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Myrdal, Caitlyn N.& Sundararajan, Srinath. Response to IpilimumabNivolumab Rechallenge and BRAF InhibitorMEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy. Case Reports in Oncological Medicine. 2020. Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1149406
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1149406
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر